|1.||Albrecht, Janice K: 9 articles (05/2014 - 11/2003)|
|2.||Brass, Clifford A: 8 articles (05/2014 - 10/2007)|
|3.||Berg, Thomas: 8 articles (06/2013 - 07/2006)|
|4.||Albrecht, Janice: 7 articles (02/2011 - 05/2002)|
|5.||Prous, J R: 7 articles (09/2007 - 06/2004)|
|6.||Rabasseda, X: 7 articles (09/2007 - 06/2004)|
|7.||Manns, Michael P: 6 articles (05/2014 - 09/2003)|
|8.||Pedicone, Lisa D: 6 articles (05/2014 - 08/2009)|
|9.||Burroughs, Margaret: 6 articles (05/2014 - 05/2009)|
|10.||Poynard, Thierry: 6 articles (03/2013 - 05/2002)|
|1.||Chronic Hepatitis C
04/01/2010 - "Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials."
02/01/2007 - "Satisfaction of patients treated for chronic hepatitis C with the peginterferon alfa-2b pen device: the VISA observational study."
12/01/2013 - "Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C."
12/01/2010 - "Proceed with caution: peginterferon alpha-2a versus peginterferon alfa-2b in chronic hepatitis C. "
12/01/2007 - "A systematic review of the cost-effectiveness of peginterferon alfa-2b in the treatment of chronic hepatitis C."
01/15/2013 - "For genotype 2 or 3 infection, dual therapy for 12 to 16 weeks was associated with a lower likelihood of SVR than was therapy for 24 weeks, and lower doses of pegylated interferon alfa-2b were less effective than standard doses (2 to 4 fair-quality trials). "
03/01/2006 - "Patients whose infection did not spontaneously resolve by week 8 were randomized to once weekly peginterferon alfa-2b monotherapy (1.5 microg/kg per week) started at weeks 8, 12, or 20 for a duration of 12 weeks. "
06/01/2005 - "Pegylated interferon alfa-2b (PEG-IFN-alfa 2b ) has been shown to provide superior efficacy to IFN-alfa 2b in patients with chronic hepatitis C (predominantly genotype 1) infection as measured by viral clearance. "
07/15/2002 - "Studies in patients with chronic hepatitis C infection and malignancies have demonstrated both biologic and clinical activity of PEG Intron and have provided empiric data to compare the pharmacokinetics (PK) and pharmacodynamics of PEG Intron and IFN-alpha-2b. "
06/01/2005 - "Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection."
03/01/2006 - "This randomized trial assessed the efficacy, safety, and timing of pegylated interferon alfa-2b for treatment of acute hepatitis C. "
08/01/2006 - "Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response."
03/01/2006 - "Peginterferon alfa-2b monotherapy in acute hepatitis C induces high sustained virologic response rates, prevents chronic evolution, and is well tolerated. "
03/01/2006 - "Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response."
02/01/2005 - "Peginterferon alfa-2b treatment for patients affected by acute hepatitis C: presentation of six case reports."
|4.||Chronic Hepatitis B
08/21/2013 - "Serum samples were obtained from patients with chronic hepatitis B who were receiving peginterferon alfa-2b. "
01/08/2005 - "Treatment with pegylated interferon alfa-2b is effective for HBeAg-positive chronic hepatitis B. "
01/01/2006 - "Similar efficacy of peginterferon alfa-2b has also been demonstrated in HBeAg-positive chronic hepatitis B. "
12/01/2014 - "Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: a randomized trial."
08/21/2013 - "Serum proteins in chronic hepatitis B patients treated with peginterferon alfa-2b."
09/15/2002 - "We conducted a phase I/II study to determine the maximum-tolerated dose (MTD), the safety and tolerability, and the preliminary efficacy of once-weekly pegylated interferon alfa-2b (IFNalpha-2b) in patients with advanced solid tumors (primarily RCC). "
07/15/2002 - "Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation."
09/15/2002 - "Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study."
03/01/2003 - "Pegylated interferon alfa-2b as treatment of patients with solid tumors."
07/15/2002 - "Dose intensification can be achieved safely in patients with CML and solid tumors using PEG Intron, which could improve efficacy. "
|3.||peginterferon alfa-2b (Pegintron)
|4.||peginterferon alfa-2a (Pegasys)
|5.||Hepatitis B e Antigens
|6.||Interferon Alfa-2b (Interferon Alfa 2b)
|9.||N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamide
|10.||Interferon-alpha (Interferon Alfa)
|5.||Drug Therapy (Chemotherapy)